TD Cowen reiterates Buy on Ionis Pharmaceuticals
TD Cowen analyst Yaron Werber has reiterated a Buy rating on Ionis Pharmaceuticals, maintaining a price target of $108. The endorsement underscores confidence in the biotechnology company's stock performance potential.
*this image is generated using AI for illustrative purposes only.
TD Cowen analyst Yaron Werber has reaffirmed a Buy rating on Ionis Pharmaceuticals, maintaining a price target of $108. The endorsement underscores confidence in the biotechnology company's stock performance potential.
Analyst Rating and Price Target
The rating reiteration comes as the firm holds steady on its valuation outlook for Ionis Pharmaceuticals. The following table details the current analyst stance:
| Metric | Value |
|---|---|
| Rating | Buy |
| Price Target | $108 |
The $108 price target suggests an expected upside based on the company's current trading levels. The Buy rating indicates that the analyst believes the stock will outperform the broader market.
What upcoming clinical trial readouts could serve as the primary catalysts for reaching the $108 price target?
How might Ionis Pharmaceuticals' pipeline diversification impact its long-term revenue stability and growth prospects?
What competitive threats does Ionis face in its key therapeutic areas, and how could these affect market share?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
